DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dogwood Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.21−0.01 (-0.82%)
Close on Oct 19, 2026
- Market cap
- $41.30M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
11.3%
4M of 34M shares
Institutional holders
15
5 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Steven Boyd | 3,384,798 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Armistice Capital, LLC | 3,343,120 | 9.99% | 13G (passive) | Mar 31, 2026 |
| CK Life Sciences Int'l., (Holdings) Inc. | 24,664,971 | 83.00% | 13D (active) amendment | Nov 21, 2025 |
| Sealbond Limited | 211,383 | 15.90% | 13D (active) amendment | Mar 12, 2025 |
| Orca Capital AG | 115,790 | 6.10% | 13G (passive) | Mar 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DWTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 3,132,486 | 9.22% | $5.04M | −147,514 | 0.06% |
| Millennium Management LLC | 341,814 | 1.01% | $550.32K | New | 0.00% |
| Vanguard Capital Management LLC | 132,154 | 0.39% | $212.77K | – | 0.00% |
| Geode Capital Management, LLC | 88,298 | 0.26% | $142.16K | +8,864 | 0.00% |
| Vanguard Fiduciary Trust Co | 62,736 | 0.18% | $101.01K | – | 0.00% |
| BlackRock, Inc. | 28,546 | 0.08% | $45.96K | +28,516 | 0.00% |
| Northern Trust Corp | 23,779 | 0.07% | $38.28K | – | 0.00% |
| Citadel Advisors LLC | 11,742 | 0.03% | $18.91K | New | 0.00% |
| Tower Research Capital LLC (TRC) | 3,093 | 0.01% | $4.98K | −4,974 | 0.00% |
| Morgan Stanley | 2,222 | 0.01% | $3.58K | New | 0.00% |
| UBS Group AG | 1,860 | 0.01% | $3.00K | −5,225 | 0.00% |
| Jones Financial Companies Lllp | 160 | 0.00% | $264 | New | 0.00% |
| Barclays PLC | 157 | 0.00% | $253 | New | 0.00% |
| Activest Wealth Management | 120 | 0.00% | $193 | – | 0.00% |
| Group One Trading, L.P. | 9 | 0.00% | $14 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 15 | 4M | 11.3% | 5 / 2 | 3 / 3 | 0M | 0M |
| Q1 2026 | 13 | 4M | 10.6% | 6 / 3 | 0 / 2 | 4M | 0M |
| Q4 2025 | 10 | 0M | 0.2% | 2 / 3 | 2 / 4 | 0M | 0M |
| Q3 2025 | 12 | 0M | 0.1% | 3 / 2 | 4 / 1 | 0M | 0M |
| Q2 2025 | 10 | 0M | 0.1% | 1 / 2 | 3 / 4 | 0M | 0M |
| Q1 2025 | 13 | 0M | 0.2% | 4 / 4 | 1 / 1 | 0M | 0M |
| Q4 2024 | 10 | 0M | 0.1% | 10 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DWTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 132,154 | 0.39% | $212.77K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 57,163 | 0.17% | $96.61K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 26,624 | 0.08% | $42.86K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 13,059 | 0.04% | $22.07K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,294 | 0.01% | $3.88K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,892 | 0.01% | $3.05K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 880 | 0.00% | $1.49K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gregory Scott Duncan | CHIEF EXECUTIVE OFFICER, Director | 57,461 | 0.17% | Mar 6, 2026 |
| Roger Michael Gendreau | CHIEF MEDICAL OFFICER | – | – | Mar 6, 2026 |
| Angela Walsh | Chief Financial Officer | 3,000 | 0.01% | Mar 6, 2026 |
| Ralph Grosswald | SVP OF OPERATIONS | – | – | Mar 6, 2026 |
| John C. Thomas | Director | 1,000 | 0.00% | Jun 17, 2026 |
| David R. Keefer | Director | 12,808 | 0.04% | Jun 17, 2026 |
| Richard James Whitley | Director | 700 | 0.00% | Jun 17, 2026 |
| La Rosa Abel De | Director | 4,000 | 0.01% | Jun 17, 2026 |
| Inc. Conjoint | Director, 10% owner | 24,664,971 | 72.56% | Nov 25, 2025 |
| Ltd Sealbond | Director, 10% owner | 211,383 | 0.62% | Nov 25, 2025 |
| Life Sciences Intl (Holdings) Inc CK | Director, 10% owner | – | – | Nov 25, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Inc. Conjoint Director, 10% owner | Nov 21, 2025 | Conversion | +21,610,950 | – | – | 21,822,333 |
| Inc. Conjoint Director, 10% owner | Nov 21, 2025 | Conversion | +2,842,638 | – | – | 2,842,638 |
| William Pridgen Director | Aug 21, 2023 | Buy | +15,335 | $1.30 | $19.94K | 52,045 |
| Gregory Scott Duncan CHIEF EXECUTIVE OFFICER, Director | Aug 17, 2023 | Buy | +25,000 | $1.25 | $31.25K | 57,461 |
| Richard James Whitley Director | Dec 8, 2022 | Sale | −1,800 | $0.26 | $468 | 700 |
| Gregory Scott Duncan CHIEF EXECUTIVE OFFICER, Director | May 23, 2022 | Buy | +7,500 | $4.52 | $33.90K | 32,461 |
| Angela Walsh SVP OF FINANCE | May 23, 2022 | Buy | +2,000 | $4.58 | $9.16K | 3,000 |
| Richard James Whitley Director | May 18, 2022 | Buy | +500 | $4.53 | $2.27K | 2,500 |
| William Pridgen Director | May 18, 2022 | Buy | +241 | $4.50 | $1.08K | 36,710 |
| William Pridgen Director | May 17, 2022 | Buy | +13,450 | $4.38 | $58.91K | 36,469 |
| William Pridgen Director | Mar 29, 2022 | Buy | +600 | $4.94 | $2.96K | 23,019 |
| William Pridgen Director | Mar 23, 2022 | Buy | +2,197 | $5.46 | $12.00K | 22,419 |
| William Pridgen Director | Jan 27, 2022 | Buy | +4,180 | $5.98 | $25.00K | 18,722 |
| La Rosa Abel De Director | Jan 7, 2022 | Buy | +4,000 | $5.90 | $23.60K | 4,000 |
| Richard James Whitley Director | Jan 6, 2022 | Buy | +1,800 | $5.72 | $10.30K | 2,000 |
| David R. Keefer Director | Jan 4, 2022 | Buy | +5,000 | $5.80 | $29.00K | 5,000 |
| John C. Thomas Director | Jan 4, 2022 | Buy | +1,000 | $5.65 | $5.65K | 1,000 |
| William Pridgen Director | Jan 3, 2022 | Buy | +2,215 | $5.43 | $12.03K | 14,542 |
| Richard James Whitley Director | Dec 23, 2021 | Buy | +200 | $5.73 | $1.15K | 200 |
| William Pridgen Director | Dec 21, 2021 | Buy | +8,827 | $5.66 | $49.96K | 12,327 |
| Gregory Scott Duncan CHIEF EXECUTIVE OFFICER, Director | Dec 21, 2021 | Buy | +5,000 | $5.52 | $27.60K | 24,961 |
| William Pridgen Director | Jul 7, 2021 | Buy | +942 | $6.32 | $5.95K | 710,734 |
| Gregory Scott Duncan Chief Executive Officer, Director | Apr 6, 2021 | Buy | +382 | $6.36 | $2.43K | 19,961 |
| Gregory Scott Duncan Chief Executive Officer, Director | Apr 5, 2021 | Buy | +15,675 | $6.17 | $96.71K | 19,579 |
| Gregory Scott Duncan Chief Executive Officer, Director | Apr 5, 2021 | Buy | +15,675 | $6.17 | $96.71K | 19,579 |
| William Pridgen Director | Jan 29, 2021 | Buy | +3,500 | $7.47 | $26.15K | 3,500 |
| Angela Walsh VP of Finance | Jan 28, 2021 | Buy | +1,000 | $7.30 | $7.30K | 1,000 |
| David R. Keefer Director | Jan 28, 2021 | Option exercise | +1,602 | $7.80 | $12.50K | 7,808 |
| William Pridgen Director | Jan 28, 2021 | Option exercise | +801 | $7.80 | $6.25K | 727,993 |
| Gregory Scott Duncan Chief Executive Officer, Director | Jan 6, 2021 | Option exercise | +801 | $7.80 | $6.25K | 3,904 |
| William Pridgen Director | Dec 17, 2020 | Buy | +1,500 | $11.98 | $17.97K | 727,192 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.